Disarm Therapeutics Inc., of Cambridge, Mass., published two articles in Science about the structure and function of SARM1, a protein that helps regulate cellular degeneration. Both articles involve the centrality of the NAD+-cleavage pathway in mediating cellular degeneration across multiple species. Disarm is working on treatments for multiple sclerosis, amyotrophic lateral sclerosis, and peripheral neuropathies.